Open company graph database — free web & API
Login

Renascience Inc.

株式会社レナサイエンス
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
12
Related companies
8
§01

Basic information

BASIC
Head office
202, 6th Building, Medical School, 2-1 Seiryou-cho, Aoba-ku, Sendai, Miyagi Prefecture
Chief executive
Toshio Miyata
Capital
1,982,422,000  (19 100 million)
Employees (non-consolidated)
3 people
Employees (consolidated)
12 people
Start date
2000-02-15
End date
§02

Websites

1 DOMAINS
§03

Business

3
Drug DevelopmentMedical Device DevelopmentAI-Enabled Programmed Medical Device Development
§04

Related companies

8 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Taipei Medical University (TMU) - Biotech Corporation
Group
GMO Click Securities Inc.
Customer
Matsui Securities Co., Ltd.
Customer
Rakuten Securities, Inc.
Customer
Ueda Hachiyagi Short-term Securities Co., Ltd.
Shareholder
SBI SECURITIES Co.,Ltd.
Shareholder
SMBC Trust Bank, Inc.
Shareholder
First Realtor Inc.
Shareholder
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

45 EVENTS

Established Renascience Inc. as a university-originated startup in Yokohama City, Kanagawa Prefecture.Sources

Founded Renascience Inc. as an academic bio-venture company in Kanagawa, JapanSources

Listed shares on the Tokyo Stock Exchange Mothers market (now Growth market) (ticker code: 4889).Sources

Listed on the Tokyo Stock Exchange Mothers market (current Growth market, securities code: 4889)Sources

Established the Tohoku University Renascience Open Innovation Lab (TREx).Sources

Open Tohoku University Renascience Open Innovation Labo (TREx)Sources

Initiated Phase III trial for chronic myeloid leukemia.Sources

Initiation of dosing in a PhaseⅢ study of chronic myeloid leukemiaSources

Obtained regulatory approval for disposable ultra-thin endoscope.Sources

Regulatory Approval of Ultrafine Disposable EndoscopeSources

Established the Hiroshima University Renascience Open Innovation Lab (HiREx).Sources

Open Hiroshima University Renascience Open Innovation Labo (HiREx)Sources

Obtained proof of concept in Phase II trial for malignant melanoma.Sources

Obtained POC in Phase II study for malignant melanomaSources

Initiated Phase II trial for non-small cell lung cancer therapy.Sources

Initiation of Phase II Study for Non-Small Cell Lung CancerSources

Initiated Phase II trial for interstitial lung disease associated with systemic sclerosis.Sources

Initiated Phase II trial for cutaneous vascular sarcoma therapy.Sources

Initiation of Phase II Study for interstitial lung disease associated with systemic sclerodermaSources

Initiation of Phase II Study for Cutaneous AngiosarcomaSources

Initiation of Phase II study for interstitial lung disease associated with systemic sclerodermaSources

Initiated Phase I clinical trial for androgenetic alopecia (age-related hair loss) at Eirion.Sources

Initiation of Phase I clinical trial for male pattern baldness (age-related alopecia) by Eirion inc.Sources

Designated as a rare disease drug by the Ministry of Health, Labour and Welfare for malignant melanoma therapy.Sources

Rare disease drug designation for malignant melanoma treatment drugSources

Relocated headquarters from Nihonbashi, Chuo-ku, Tokyo to Sendai City, Miyagi Prefecture.Sources

Relocated its head office from Nihonbashi, Chuo-ku, Tokyo to Sendai City, Miyagi Prefecture.Sources

Initiated Phase III trial for malignant melanoma.Sources

Initiation of the Phase III trial of malignant melanoma treatment drug RS5614Sources

Placed in the Top 40 of the global longevity research competition XPRIZE Healthspan.Sources

Top 40 winner of the XPRIZE Healthspan, a global longevity research competitionSources

Issued new shares and stock options through a third-party allotment.Sources

Issuance of new shares and stock acquisition rights through third-party allotmentSources

Issuance of new shares and stock acquisition rights through the first third-party allotmentSources

Issuance of new shares and stock acquisition rights through the 1st third-party allotmentSources

Issuance of new shares and stock acquisition rights through the second third-party allotmentSources

Issuance of new shares and stock acquisition rights through the 2nd third-party allotmentSources

Issuance of new shares and stock acquisition rights through the third third-party allotmentSources

Issuance of new shares and stock acquisition rights through the 3rd third-party allotmentSources

Issuance of new shares and stock acquisition rights through the fourth third-party allotmentSources

Issuance of new shares and stock acquisition rights through the 4th third-party allotmentSources

Initiation of the late-stage Phase II study for non-small cell lung cancerSources

Initiation of the Phase II study for pancreatic cancerSources

Initiation of a Phase II Trial for Pancreatic CancerSources

Initiation of a phase II trial for locally advanced non-small cell lung cancerSources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information1012301007259
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社レナサイエンス
Trade name (kana)
レナサイエンス
Name in English
Corporation type
301
Address
〒980-0872 宮城県仙台市青葉区星陵町2番1号
Postal code
9800872
Prefecture code
04
City code
101
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2024-10-21
Change date
2024-10-08
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
304834
METI gBizINFO1012301007259
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
1012301007259
Trade name
株式会社レナサイエンス
Trade name (kana)
レナサイエンス
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
宮城県仙台市青葉区星陵町2番1号
Postal code
9800872
Prefecture
宮城県
Prefecture code
04
City or district
仙台市青葉区
City code
101
Street address
星陵町2番1号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役会長兼社長 宮田 敏男
Capital
1982422000
Employees
3
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2024-10-21
Key information
1012301007259
§09

Sources & updates

SOURCES
↑